Tributyrin plus all-trans-retinoic acid efficiently induces fetal hemoglobin expression in human erythroleukemia cells.
Fourteen butyrate derivatives and retinoic acid were tested with respect to the hemoglobin F-inducing activity using the K562 erythroleukemia cell line as a model system. Four novel butyrate derivatives with hemoglobin F-inducing activity have been identified. Combined treatment with the butyrate derivative tributyrin and retinoic acid in vitro led to a 7-fold increase of hemoglobin synthesis. Tributyrin and retinoic acid might be promising drugs for clinical trials to treat patients with beta-hemoglobinopathies.
Children's Hospital, University of Göttingen, Göttingen, Germany.
O
O
Witt
S
S
Schmejkal
A
A
Pekrun
D000970:Antineoplastic Agents / Q000494:pharmacology*; D005319:Fetal Hemoglobin / Q000096:biosynthesis*; D006801:Humans; D020014:K562 Cells; D004915:Leukemia, Erythroblastic, Acute / Q000378:metabolism*; D014212:Tretinoin / Q000494:pharmacology*; D014280:Triglycerides / Q000494:pharmacology*
D000970:Antineoplastic Agents; D014280:Triglycerides; D014212:Tretinoin; D005319:Fetal Hemoglobin; C005830:tributyrin